About

Tessera Therapeutics focuses on genetic medicine, specifically through a technology called Gene Writing, which enables precise modifications to the human genome. This technology allows for permanent changes to genetic material in any cell, aiming to cure diseases at their source. Tessera's Gene Writing can perform both small and large genetic alterations, making it applicable to a wide range of genetic disorders. The company primarily serves research institutions, pharmaceutical companies, and healthcare providers seeking to develop new treatments for genetic diseases. Unlike its competitors, Tessera Therapeutics emphasizes the versatility of its technology and its potential to address previously untreatable conditions. The company's goal is to advance the development of its Gene Writing platform to ultimately cure diseases by rewriting the genetic code.

Simplify's Take

What believers are saying

• Partnership with Gates Foundation boosts development of sickle cell disease treatment.
• $300 million Series C funding in 2022 supports platform advancement and commercialization.
• Located in Boston, Tessera benefits from a thriving biotech ecosystem.

What critics are saying

• Competition from CRISPR-based technologies may challenge Tessera's market position.
• High development costs could delay Gene Writing technology's market entry.
• Regulatory hurdles may slow approval and adoption of genetic therapies.

What makes Tessera Therapeutics unique

• Tessera Therapeutics pioneers Gene Writing, a novel approach in genetic medicine.
• Their technology allows precise genome alterations, surpassing traditional gene editing methods.
• Tessera's platform targets a wide range of genetic disorders with versatile applications.

Help us improve and share your feedback! Did you find this helpful?

YesNo